The short version is that federal lawmakers are pushing back against a proposal to place political appointees in charge of approving scientific research funding. This plan would create a commission with the power to sign off on every grant from the National Institutes of Health, a move that significantly increases White House control over biomedical research. Several members of Congress voiced strong opposition after news of the plan leaked in recent days.
What the plan actually says
According to reporting from The Washington Post, Russell Vought, the head of the White House Office of Management and Budget, pushed for an executive order during a contentious meeting at the White House on Friday. Vought advocated for the creation of a commission that would review all NIH grants. Politico reported that the proposed board would include both Vought and NIH Director Jay Bhattacharya. The board would be required to reach unanimous decisions on grants. This specific requirement means that a single member could effectively block funding if they did not agree with the other appointees.
Why the friction started
President Trump reportedly directed Vought to draft the order after becoming angry that Jay Bhattacharya had refused to cut funding for Harvard researchers. This dispute over specific grants at Harvard appears to be the immediate trigger for the broader structural change. The tension has escalated over increased White House control of federal biomedical research funding. The leak of these internal discussions has now moved the conflict from behind closed doors to public congressional debate.
In plain terms, this is a shift from an agency-led process to a political one. Currently, the NIH manages its own grant portfolio. Under the proposed commission, a group of political appointees, including the head of the budget office and the NIH director, would hold the final say. The requirement for unanimity adds a layer of complexity that could slow down or block research approvals. Lawmakers are reacting to this potential change in governance structure. The core issue is whether scientific funding should be subject to direct political oversight through a new executive body. The debate continues as Congress evaluates the implications of this new commission on the future of federal research funding.